Evidence map›Paper›PMID 38633246›Full record

ArticleFrontiers in immunology2024

The lack of PPARα exacerbated the progression of non-alcoholic steatohepatitis in mice with spleen deficiency syndrome by triggering an inflammatory response.

Jiawen Huang, Jiayu Li, Yuan Peng, Tianqi Cui, Jingyi Guo, Siwei Duan, Kaili Zhou, Shangyi Huang, Jiabing Chen, Qincheng Yi and 11 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 1 country.

Jiawen Huang *Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jiayu Li *Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yuan Peng *Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Tianqi CuiScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jingyi GuoScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Siwei DuanScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Kaili ZhouScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shangyi HuangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jiabing ChenScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Qincheng YiScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Min QiuScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Tingting ChenScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiaoqin WuScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chenlu MaScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Ziyi ZhangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yi ZhengScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xi TangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yanqing PangDepartment of Phase I Clinical Research Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China.
Lei ZhangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Chong ZhongDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Yong GaoScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNAffiliated Hospital of North Sichuan Medical College · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CNTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In addition to abnormal liver inflammation, the main symptoms of non-alcoholic steatohepatitis (NASH) are often accompanied by gastrointestinal digestive dysfunction, consistent with the concept of spleen deficiency (SD) in traditional Chinese medicine. As an important metabolic sensor, whether peroxisome proliferator-activated receptor alpha (PPARα) participates in regulating the occurrence and development of NASH with SD (NASH-SD) remains to be explored. Methods: Clinical liver samples were collected for RNA-seq analysis. C57BL/6J mice induced by folium sennae (SE) were used as an SD model. qPCR analysis was conducted to evaluate the inflammation and metabolic levels of mice. PPARα knockout mice (PPARα Results: The abnormal expression of PPARα signaling, coupled with metabolism and inflammation, was found in the results of RNA-seq analysis from clinical samples. SD mice showed a more severe inflammatory response in the liver evidenced by the increases in macrophage biomarkers, inflammatory factors, and fibrotic indicators in the liver. qPCR results also showed differences in PPARα between SD mice and control mice. In PPARα Conclusion: The abnormal NR signaling accelerated the vicious cycle between lipotoxicity and inflammatory response in NAFLD with SD. Our results provide new evidence for nuclear receptors as potential therapeutic targets for NAFLD with spleen deficiency.

Indexed as

Non-alcoholic Fatty Liver DiseasePPAR alphaAnimalsInflammationMiceMice, Inbred C57BLMice, KnockoutSpleenPPAR alphainflammatory responselipid metabolismnon-alcoholic steatohepatitisnuclear receptorPPARα

Identifiers

PMID38633246
PMCPMC11021588
OpenAlexW4393866979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.